vs
Evolv Technologies Holdings, Inc.（EVLV）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Evolv Technologies Holdings, Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$38.5M vs $30.3M），Evolv Technologies Holdings, Inc.净利率更高（28.3% vs -221.3%，领先249.6%），REGENXBIO Inc.同比增速更快（43.0% vs 32.3%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 31.8%）
该企业总部位于美国旧金山，是一家人工智能科技公司，成立于2007年，成立后累计获得超1.43亿美元投资，2016年时曾是全球融资规模最高的人工智能企业，业务聚焦电子商务、线上内容与交易领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EVLV vs RGNX — 直观对比
营收规模更大
EVLV
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出10.7%
32.3%
净利率更高
EVLV
高出249.6%
-221.3%
两年增速更快
RGNX
近两年复合增速
31.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.5M | $30.3M |
| 净利润 | $10.9M | $-67.1M |
| 毛利率 | 48.4% | — |
| 营业利润率 | -20.7% | -190.0% |
| 净利率 | 28.3% | -221.3% |
| 营收同比 | 32.3% | 43.0% |
| 净利润同比 | 169.2% | -31.2% |
| 每股收益（稀释后） | $0.07 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVLVRGNX
| Q4 25 | $38.5M | $30.3M | ||
| Q3 25 | $42.9M | $29.7M | ||
| Q2 25 | $32.5M | $21.4M | ||
| Q1 25 | $32.0M | $89.0M | ||
| Q4 24 | $29.1M | $21.2M | ||
| Q3 24 | $27.4M | $24.2M | ||
| Q2 24 | $25.2M | $22.3M | ||
| Q1 24 | $22.2M | $15.6M |
净利润EVLVRGNX
| Q4 25 | $10.9M | $-67.1M | ||
| Q3 25 | $-1.8M | $-61.9M | ||
| Q2 25 | $-40.5M | $-70.9M | ||
| Q1 25 | $-1.7M | $6.1M | ||
| Q4 24 | $-15.7M | $-51.2M | ||
| Q3 24 | $-30.4M | $-59.6M | ||
| Q2 24 | $3.4M | $-53.0M | ||
| Q1 24 | $-11.3M | $-63.3M |
毛利率EVLVRGNX
| Q4 25 | 48.4% | — | ||
| Q3 25 | 49.7% | — | ||
| Q2 25 | 49.8% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | 57.5% | 70.2% | ||
| Q3 24 | 57.8% | 48.8% | ||
| Q2 24 | 58.5% | 52.5% | ||
| Q1 24 | 54.8% | 72.6% |
营业利润率EVLVRGNX
| Q4 25 | -20.7% | -190.0% | ||
| Q3 25 | -20.1% | -176.3% | ||
| Q2 25 | -53.8% | -296.3% | ||
| Q1 25 | -45.0% | 13.6% | ||
| Q4 24 | -64.9% | -242.1% | ||
| Q3 24 | -70.0% | -256.6% | ||
| Q2 24 | -88.7% | -251.3% | ||
| Q1 24 | -98.8% | -408.8% |
净利率EVLVRGNX
| Q4 25 | 28.3% | -221.3% | ||
| Q3 25 | -4.2% | -208.3% | ||
| Q2 25 | -124.6% | -331.8% | ||
| Q1 25 | -5.3% | 6.8% | ||
| Q4 24 | -54.0% | -241.3% | ||
| Q3 24 | -111.3% | -246.3% | ||
| Q2 24 | 13.6% | -237.7% | ||
| Q1 24 | -50.8% | -405.4% |
每股收益（稀释后）EVLVRGNX
| Q4 25 | $0.07 | $-1.30 | ||
| Q3 25 | $-0.01 | $-1.20 | ||
| Q2 25 | $-0.25 | $-1.38 | ||
| Q1 25 | $-0.01 | $0.12 | ||
| Q4 24 | $-0.10 | $-0.99 | ||
| Q3 24 | $-0.19 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $-0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.1M | $230.1M |
| 总债务越低越好 | $28.6M | — |
| 股东权益账面价值 | $119.4M | $102.7M |
| 总资产 | $304.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资EVLVRGNX
| Q4 25 | $49.1M | $230.1M | ||
| Q3 25 | $56.2M | $274.2M | ||
| Q2 25 | $36.9M | $323.3M | ||
| Q1 25 | $35.0M | $267.9M | ||
| Q4 24 | $51.9M | $234.7M | ||
| Q3 24 | $56.0M | $255.5M | ||
| Q2 24 | $56.5M | $290.4M | ||
| Q1 24 | $81.0M | $338.7M |
总债务EVLVRGNX
| Q4 25 | $28.6M | — | ||
| Q3 25 | $28.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EVLVRGNX
| Q4 25 | $119.4M | $102.7M | ||
| Q3 25 | $102.2M | $161.5M | ||
| Q2 25 | $92.7M | $213.7M | ||
| Q1 25 | $121.1M | $274.2M | ||
| Q4 24 | $117.7M | $259.7M | ||
| Q3 24 | $129.0M | $301.4M | ||
| Q2 24 | $151.2M | $348.3M | ||
| Q1 24 | $139.8M | $390.7M |
总资产EVLVRGNX
| Q4 25 | $304.4M | $453.0M | ||
| Q3 25 | $304.3M | $525.2M | ||
| Q2 25 | $280.4M | $581.0M | ||
| Q1 25 | $256.0M | $490.9M | ||
| Q4 24 | $268.1M | $466.0M | ||
| Q3 24 | $278.5M | $519.1M | ||
| Q2 24 | $269.1M | $569.4M | ||
| Q1 24 | $280.0M | $629.2M |
负债/权益比EVLVRGNX
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EVLVRGNX
| Q4 25 | $15.6M | $-52.3M | ||
| Q3 25 | $3.5M | $-56.0M | ||
| Q2 25 | $2.1M | $-49.3M | ||
| Q1 25 | $-2.5M | $33.6M | ||
| Q4 24 | $3.2M | $-31.6M | ||
| Q3 24 | $3.7M | $-40.5M | ||
| Q2 24 | $-21.6M | $-45.5M | ||
| Q1 24 | $-16.2M | $-55.5M |
自由现金流EVLVRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率EVLVRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度EVLVRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率EVLVRGNX
| Q4 25 | 1.43× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.31× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVLV
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
